Harvard geneticist Dr. David Sinclair's OSK therapy (ER-100) enters human trials. Learn how cellular reprogramming could ...
Background Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to immune checkpoint blockade, owing to its ...
Thirty years after Dolly the sheep became the first cloned mammal, cloning has evolved from a sci-fi idea into a ...
As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...
Morning Overview on MSN
The first cellular age-reversal therapy has been cleared for human trials
Life Biosciences has received FDA clearance to begin a first-in-human Phase 1 clinical trial of ER-100, a gene therapy ...
A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common ...
Proprietary Synthetic Polynucleotide Platform Accelerates Non-Viral, Footprint-Free Induced Pluripotent Stem Cell Generation Amid Surging Commercialization of iPSC Therapies in JapanSEATTLE, June 16, ...
Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.
The outspoken longevity scientist David Sinclair has been predicting that one day, you’ll go to the doctor and get a prescription that will make you 10 years younger. Now MIT Technology Review has ...
Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.
Researchers from Sichuan University developed a mineralized DNA hydrogel scaffold that regulates immune responses while sustaining calcium-driven bone regeneration for improved healing of skeletal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results